Today, the U.S. Food and Drug Administration took additional steps to ensure a smooth regulatory transition aimed at increasing patient access to insulin products, as well as certain other biological products set to transition regulatory pathways in March
Read more: FDA Works to Ensure Smooth Regulatory Transition of Insulin and Other Biological Products